Related Experiment Video
Updated: May 5, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Innovative therapies in Ewing Sarcoma
Ana Teresa Amaral1, José Luis Ordóñez, Ana Pastora Otero-Motta
1*Molecular Pathology Program, Institute of Biomedical Research of Salamanca-Centro de Investigación del Cáncer, Centro de Investigación del Cancér (IBSAL-CIC), Campus Miguel de Unamuno S/N, Salamanca †Pathology Department, Hospital Universitario Virgen del Rocio-IBiS, Sevilla, Spain.
Abstract:
Ewing Sarcoma is a developmental tumor characterized by balanced chromosomal translocations and formation of new fusion genes, which are the main hallmark of this rare entity. Despite the vast knowledge regarding the molecular aspects of this rare malignancy obtained in the last few years, including the discovery of new therapeutic targets, many questions still remain open. In this review we focus on the research on targeted therapies in this malignancy, and discussed some bottlenecks related to this such as the possible role of pathologists, the availability of samples, the lack of appropriate animal models, and the resources needed to carry out preclinical and clinical research.
Insights
Ewing sarcoma, a rare developmental tumor, presents unique fusion genes. Research on targeted therapies faces challenges including sample availability and animal models.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Ewing sarcoma is a rare pediatric malignancy defined by specific chromosomal translocations and fusion genes.
- Recent advancements have identified novel molecular targets for therapeutic intervention.
Purpose of the Study:
- To review current research on targeted therapies for Ewing sarcoma.
- To discuss obstacles hindering preclinical and clinical research in this rare cancer.
Main Methods:
- Literature review of studies on Ewing sarcoma targeted therapies.
- Analysis of challenges in sample acquisition, animal modeling, and research resources.
Main Results:
- Despite molecular insights, significant challenges impede targeted therapy development.
- Pathologist involvement, sample accessibility, and suitable preclinical models are critical bottlenecks.
Conclusions:
- Overcoming research bottlenecks is crucial for advancing targeted Ewing sarcoma treatments.
- Multifaceted approaches are needed to facilitate the translation of molecular discoveries into effective therapies.
More Related Videos
07:31A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
07:50Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts
Published on: May 25, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...